Literature DB >> 32038939

CheckMate 153 study: are age and performance status relevant for immune checkpoint inhibitor efficacy?

Jose Carlos Benitez1, Jordi Remon2, Benjamin Besse1,3.   

Abstract

Year:  2019        PMID： 32038939      PMCID： PMC6987362          DOI： 10.21037/tlcr.2019.12.26

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  13 in total

1.  Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1.

Authors:  Stéphane Champiat; Laurent Dercle; Samy Ammari; Christophe Massard; Antoine Hollebecque; Sophie Postel-Vinay; Nathalie Chaput; Alexander Eggermont; Aurélien Marabelle; Jean-Charles Soria; Charles Ferté
Journal:  Clin Cancer Res       Date:  2016-11-08       Impact factor: 12.531

2.  Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).

Authors:  David R Spigel; Michael McCleod; Robert M Jotte; Lawrence Einhorn; Leora Horn; David M Waterhouse; Ben Creelan; Sunil Babu; Natasha B Leighl; Jason C Chandler; Felix Couture; George Keogh; Glenwood Goss; Davey B Daniel; Edward B Garon; Lee S Schwartzberg; Rohini Sen; Beata Korytowsky; Ang Li; Nivedita Aanur; Maen A Hussein
Journal:  J Thorac Oncol       Date:  2019-05-20       Impact factor: 15.609

3.  Pembrolizumab for advanced nonsmall cell lung cancer: Efficacy and safety in everyday clinical practice.

Authors:  Doran Ksienski; Elaine S Wai; Nicole Croteau; Ashley T Freeman; Angela Chan; Leathia Fiorino; Edward G Brooks; Zia Poonja; David Fenton; Georgia Geller; Sarah Irons; Mary Lesperance
Journal:  Lung Cancer       Date:  2019-05-18       Impact factor: 5.705

4.  Using claims-based measures to predict performance status score in patients with lung cancer.

Authors:  Ramzi G Salloum; Thomas J Smith; Gail A Jensen; Jennifer Elston Lafata
Journal:  Cancer       Date:  2010-10-18       Impact factor: 6.860

Review 5.  Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.

Authors:  Jordi Remon; Myung-Ju Ahn; Nicolas Girard; Melissa Johnson; Dong-Wan Kim; Gilberto Lopes; Rathi N Pillai; Benjamin Solomon; Guillermo Villacampa; Qing Zhou
Journal:  J Thorac Oncol       Date:  2019-04-16       Impact factor: 15.609

Review 6.  Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

Authors:  Tomohiro F Nishijima; Hyman B Muss; Shlomit S Shachar; Stergios J Moschos
Journal:  Cancer Treat Rev       Date:  2016-03-02       Impact factor: 12.111

7.  Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Authors:  Leora Horn; David R Spigel; Everett E Vokes; Esther Holgado; Neal Ready; Martin Steins; Elena Poddubskaya; Hossein Borghaei; Enriqueta Felip; Luis Paz-Ares; Adam Pluzanski; Karen L Reckamp; Marco A Burgio; Martin Kohlhäeufl; David Waterhouse; Fabrice Barlesi; Scott Antonia; Oscar Arrieta; Jérôme Fayette; Lucio Crinò; Naiyer Rizvi; Martin Reck; Matthew D Hellmann; William J Geese; Ang Li; Anne Blackwood-Chirchir; Diane Healey; Julie Brahmer; Wilfried E E Eberhardt
Journal:  J Clin Oncol       Date:  2017-10-12       Impact factor: 44.544

8.  Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer.

Authors:  Francesco Grossi; Carlo Genova; Lucio Crinò; Angelo Delmonte; Daniele Turci; Diego Signorelli; Antonio Passaro; Hector Soto Parra; Annamaria Catino; Lorenza Landi; Francesco Gelsomino; Marcello Tiseo; Gianfranco Puppo; Fausto Roila; Serena Ricciardi; Giuseppe Tonini; Francesco Cognetti; Luca Toschi; Davide Tassinari; Alessandro Scoppola; Diana Giannarelli; Enrico Cortesi
Journal:  Eur J Cancer       Date:  2019-10-28       Impact factor: 9.162

9.  Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.

Authors:  Giulia Galli; Alessandro De Toma; Filippo Pagani; Giovanni Randon; Benedetta Trevisan; Arsela Prelaj; Roberto Ferrara; Claudia Proto; Diego Signorelli; Monica Ganzinelli; Nicoletta Zilembo; Filippo de Braud; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Lung Cancer       Date:  2019-09-10       Impact factor: 5.705

10.  Efficacy and Safety of Nivolumab in Patients with Advanced Non-small-cell Lung Cancer and Poor Performance Status.

Authors:  Hideyuki Katsura; Yukio Suga; Tomoyuki Araya; Toshiyuki Kita; Taro Yoneda; Nobuyoshi Tanaka; Ayumi Kawabata; Sotoki Ishita; Hiroki Mase
Journal:  J Cancer       Date:  2019-05-19       Impact factor: 4.207
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.